-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On April 12, the "2+4" Alliance of Xinjiang Uygur Autonomous Region and Xinjiang Production and Construction Corps organized the implementation plan for centralized drug procurement and use (draft for comments) (hereinafter referred to as "draft for comments")
It is worth noting that the "Notice of Xinjiang Leading Organization Inter-provincial Alliance Drug Centralized Procurement" issued by the Qinghai Provincial Medical Insurance Bureau a few days ago has been circulated in the industry, involving ten varieties, including amoxicillin and clavulanate potassium, aspirin, and C.
Xinjiang stated that by 2025, it will achieve centralized procurement of more than 500 varieties of drugs at the provincial level (including national and inter-provincial alliances) and more than 5 types of high-value medical consumables
Increase the proportion of agreed purchases based on the decline
The "Draft for Comments" shows that among the drugs that have never been included in the scope of centralized drug procurement by the national organization, priority will be given to the selection of drugs in the basic medical insurance drug catalog with large amounts, high purchase amounts, sufficient competition, and mature clinical use.
At the same time, according to the characteristics of the purchased drugs, the market structure and the competitive situation, the evaluation group will be determined, and the shortlisted companies will be selected according to the methods of negotiation, bargaining and bidding
The declared price of drugs that have been purchased in other provinces, cities, or alliance provinces in a centralized manner cannot be higher than the average price of the selected prices, and the declared prices of drugs that have not been purchased in a centralized manner shall not be higher than the minimum procurement being implemented by the national provincial procurement platform Price
It is worth noting that in addition to all public medical institutions and military medical institutions in the alliance area, designated chronic disease retail pharmacies in the Xinjiang Uygur Autonomous Region and Xinjiang Production and Construction Corps will also join the mass procurement alliance to purchase chronic disease drugs
Union procurement section played a substantial price reduction to accelerate the varieties involved
A few days ago, a "Notice of the Qinghai Provincial Medical Security Bureau Office on Filling in Data Related to the Centralized Procurement of Drugs by Xinjiang's Leading Organization of the Inter-provincial Alliance" circulated in the industry, requiring relevant data to be completed before April 12
According to the information in the form, Qinghai's participation in Xinjiang-led coalition sampling may involve 10 varieties, including: amoxicillin and clavulanate potassium, aspirin, sodium valproate, etc.
According to data from Mi Nei.
Up to now, together with the "2+4" alliance led by Xinjiang, seven inter-provincial alliances have emerged across the country, namely: the 11 provincial alliances led by Shaanxi; the five provincial alliances led by Chongqing; and the "six provinces and two districts" led by Sichuan Alliance; the 11-province alliance led by Guangdong; the Beijing-Tianjin-Hebei "3+N" alliance, and the "Yangtze River Delta Alliance" that has not yet announced the official procurement documents
The scale of the alliance's procurement and price reduction cannot be underestimated, and its influence is constantly increasing
(Note: The form is circulated in the industry, and the official release shall prevail)